| Literature DB >> 20232280 |
C David Adair1, Vardaman M Buckalew, Steven W Graves, Garrett K Lam, Donna D Johnson, George Saade, David F Lewis, Christopher Robinson, Theodore M Danoff, Nikhil Chauhan, Moana Hopoate-Sitake, Kathy B Porter, Rachel G Humphrey, Kenneth F Trofatter, Erol Amon, Suzanne Ward, Lizbeth Kennedy, Lorrie Mason, J Andrew Johnston.
Abstract
We evaluated the efficacy, safety, and biological mechanisms of digoxin immune Fab (DIF) treatment of severe preeclampsia. Fifty-one severe preeclamptic patients were randomized in double-blind fashion to DIF ( N = 24) or placebo ( N = 27) for 48 hours. Primary outcomes were change in creatinine clearance (CrCl) at 24 to 48 hours and antihypertensive drug use. Serum sodium pump inhibition, a sequela of endogenous digitalis-like factors (EDLF), was also assessed. CrCl in DIF subjects was essentially unchanged from baseline versus a decrease with placebo (-3 +/- 10 and -34 +/- 10 mL/min, respectively, P = 0.02). Antihypertensive use was similar between treatments (46 and 52%, respectively, P = 0.7). Serum sodium pump inhibition was decreased with DIF compared with placebo at 24 hours after treatment initiation (least squares mean difference, 19 percentage points, P = 0.03). DIF appeared to be well tolerated. These results suggest DIF prevents a decline in renal function in severe preeclampsia by neutralizing EDLF. Sodium pump inhibition was significantly improved. Further research is warranted. Copyright Thieme Medical Publishers.Entities:
Mesh：
Substances：
Year: 2010 PMID： 20232280 DOI： 10.1055/s-0030-1249762
Source DB: PubMed Journal: Am J Perinatol ISSN： 0735-1631 Impact factor: 1.862